Skip to content

Homoeopathic management of Hypothyroidism

Efficacy of individualized homoeopathic medicines as standalone or as an add on to standard of care on symptom profile of hypothyroidism – an open label feasibility cohort multiple randomized controlled trial. - NIL

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/04/065888
Enrollment
200
Registered
2024-04-18
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E039- Hypothyroidism, unspecified

Interventions

Intervention1: Individualised Homoeopathic medicines and Standard treatment (Levothyroxine): Homoeopathic medicines will be administered orally and repeated as per need of case till one year. Levothyr

Sponsors

CCRH
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: i. Patients suffering from hypothyroidism (serum TSH within normal range or = 20 µIU/ml) for at least last 3 months and undergoing standard therapy, i.e. Levothyroxine sodium in personalized dosage as decided by the conventionally trained endocrinologists. ii. Fresh cases of hypothyroidism (undergoing no treatment) with Serum TSH within 10- 20 µIU/ml. iii. Age: 15- 50 years. iv. Literate and illiterate patients; ability to understand Hindi. v. Patients giving written consent to participate.

Exclusion criteria

Exclusion criteria: i) TSH above 20 µIU/ml ii) Patients suffering from congenital hypothyroidism iii) Patients with psychiatric diseases iv) Pregnancy and lactation v) Cases suffering from any other uncontrolled systemic illness or life-threatening infections or any vital organ failure vi) Cases already undergoing homoeopathic treatment for any chronic diseases vii) Substance abuse and/or dependence

Design outcomes

Primary

MeasureTime frame
Changes in symptom profile related to hypothyroidism and Quality of life in patients at of 12 months (Zulewski’s clinical score at every month, Thyroid symptom questionnaire and SF-8 Questionnaire for QOL at every follow up).Timepoint: 12 months

Secondary

MeasureTime frame
To evaluate a) Changes in TSH level at every 4 weeks. b) Changes in Blood thyroid profile at 3rd, 6th, 9th, and 12th month. c) Reduction in dosage of LT-4 intake in add on group during a period of 12 month. d) Number of patients requiring LT-4 by 12 months in standalone group. e) Adverse events if any. Timepoint: 3rd- 12th month

Countries

India

Contacts

Public ContactLIPIPUSHPA DEBATA

CENTRAL COUNCIL FOR RESEARCH IN HOMOEOPATHY Ministry of Ayush Govt of India

varanasiroja@gmail.com9999454036

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026